• Genprex received a Nasdaq notice on June 10, 2026, citing noncompliance with the $1 minimum bid price rule after 30 straight business-day closes below $1.
• Nasdaq staff moved to delist the stock, citing ineligibility for a standard compliance period due to a reverse split on Oct. 21, 2025.
• A timely hearing request will stay any suspension or delisting while a Nasdaq panel reviews the case.
• Regaining compliance requires a closing bid of at least $1 for 10 consecutive business days, subject to panel discretion.
• Options include another reverse stock split; delisting could pressure the share price, reduce liquidity, and hinder access to capital markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-020501), on June 12, 2026, and is solely responsible for the information contained therein.